Natural killer cells (or NK cells) are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virally infected cells and respond to tumor formation, acting at around 3 days after infection. Typically immune cells detect MHC presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named “natural killers” because of the initial notion that they do not require activation in order to kill cells that are missing “self” markers of major histocompatibility complex (MHC) class 1.[1]
NK cells (belonging to the group of Innate lymphoid cells) are defined as large granular lymphocytes (LGL) and constitute the third kind of cells differentiated from the common lymphoid progenitor generating B and T lymphocytes.[2] NK cells are known to differentiate and mature in the bone marrow, lymph node, spleen, tonsils and thymus where they then enter into the circulation.[3] NK cells differ from Natural Killer T cells (NKT) phenotypically, by origin and by respective effector functions; often NKT cell activity promotes NK cell activity by secreting IFNγ. In contrast to NKT cells, NK cells do not express T-cell antigen receptors (TCR) or Pan T marker CD3 or surface immunoglobulins (Ig) B cell receptors, but they usually express the surface markers CD16 (FcγRIII) and CD56 in humans, NK1.1 or NK1.2 in C57BL/6 mice. Up to 80% of human NK cells also express CD8.
In addition to the knowledge that natural killer cells are effectors of innate immunity, recent research has uncovered information on both activating and inhibitory NK cell receptors which play important function roles including self tolerance and sustaining NK cell activity. NK cell also play a role in adaptive immune response,[4] numerous experiments have worked to demonstrate their ability to readily adjust to the immediate environment and formulate antigen-specific immunological memory, fundamental for responding to secondary infections with the same antigen. The ability for NK cells to act in both the innate and adaptive immune response is becoming increasingly important in research utilizing NK cell activity and potential cancer therapies.
Contents
- 1 NK cell receptors
- 2 Function
- 2.1 Cytolytic granule mediated cell apoptosis
- 2.2 Antibody-dependent cell-mediated cytotoxicity (ADCC)
- 2.3 Cytokine-induced NK and CTL activation
- 2.4 Missing 'self' hypothesis
- 2.5 Tumor cell surveillance
- 2.6 NK cell function in adaptive response
- 2.7 NK cell function in pregnancy
- 2.8 NK cell evasion by tumor cells
- 3 History
- 4 New findings
- 4.1 Anti-cancer therapy
- 4.2 Innate resistance to HIV?
- 5 See also
- 6 Literature
- 7 References
- 8 External links
NK cell receptors[edit]
NK cell receptors can also be differentiated based on function. Natural cytotoxicity receptors directly induce apoptosis after binding to ligands that directly indicate infection of a cell. The MHC dependent receptors (described above) use an alternate pathway to induce apoptosis in infected cells. Natural killer cell activation is determined by the balance of inhibitory and activating receptor stimulation i.e. if the inhibitory receptor signaling is more prominent then NK cell activity will be inhibited, similarly if the activating signal is dominant then NK cell activation will result.[5]
Protein Structure of NKG2D
NK cell receptor types (with inhibitory as well as some activating members) are differentiated by structure, with a couple of examples to follow:
Protein Structure of NKp44
Activating receptors[edit]
- Ly49 (homodimers) — a relatively ancient, C-type lectin family receptor; are of multigenic presence in mice, while humans have only one pseudogenic Ly49; the receptor for classical (polymorphic) MHC I molecules.
- NCR (natural cytotoxicity receptors), upon stimulation, mediate NK killing and release of IFNϒ.
- CD94 : NKG2 (heterodimers) — a C-type lectin family receptor, conserved in both rodents and primates and identifies non-classical (also non-polymorphic) MHC I molecules like HLA-E. Expression of HLA-E at the cell surface is dependent on the presence of nonamer peptide epitope derived from the signal sequence of classical MHC class I molecules, which is generated by the sequential action of signal peptide peptidase and the proteasome. Though indirect, this is a way to survey the levels of classical (polymorphic) HLA molecules.
- CD16 (FcγIIIA) play a role in antibody-dependent cell-mediated cytotoxicity (ADCC), in particular they bind IgG.
Function[edit]
Cytolytic granule mediated cell apoptosis[edit]
NK cells are cytotoxic; small granules in their cytoplasm contain proteins such as perforin and proteases known as granzymes. Upon release in close proximity to a cell slated for killing, perforin forms pores in the cell membrane of the target cell, creating an aqueous channel through which the granzymes and associated molecules can enter, inducing either apoptosis or osmotic cell lysis. The distinction between apoptosis and cell lysis is important in immunology: lysing a virus-infected cell could potentially only release the virions, whereas apoptosis leads to destruction of the virus inside. αdefensins, an antimicrobial is also secreted by NK cells, directly kills bacteria by disrupting their cell walls analogous to neutrophils.[3]
Antibody-dependent cell-mediated cytotoxicity (ADCC)[edit]
Infected cells are routinely poisoned with antibodies for detection by immune cells. Antibodies that bind to antigens can be recognised by FcϒRIII (CD16) receptors expressed on NK cells resulting in NK activation, release of cytolytic granules and consequent cell apoptosis. This is a major mechanism of killing for some monoclonal antibodies like rituximab (Rituxan), ofatumumab (Azzera) and others. The contribution of ADCC to tumor cell killing can be measured with a specific test that uses NK-92 that has been transfected with a high-affinity FcR. Results are compared to the "wild type" NK-92 that does not express the FcR.[6]
Cytokine-induced NK and CTL activation[edit]
Cytokines play a crucial role in NK cell activation. As these are stress molecules released by cells upon viral infection, they serve to signal to the NK cell the presence of viral pathogens. Cytokines involved in NK activation include IL-12, IL-15, IL-18, IL-2, and CCL5. NK cells are activated in response to interferons or macrophage-derived cytokines. They serve to contain viral infections while the adaptive immune response is generating antigen-specific cytotoxic T cells that can clear the infection. NK cells work to control viral infections by secreting IFNγ and TNFα. IFNγ activates macrophages for phagocytosis and lysis, and TNFα acts to promote direct NK tumor cell killing. Patients deficient in NK cells prove to be highly susceptible to early phases of herpes virus infection.
Missing 'self' hypothesis[edit]
Schematic diagram indicating the complementary activities of cytotoxic T-cells and NK cells.
In order for NK cells to defend the body against viruses and other pathogens, they require mechanisms that enable the determination of whether a cell is infected or not. The exact mechanisms remain the subject of current investigation, but recognition of an "altered self" state is thought to be involved. To control their cytotoxic activity, NK cells possess two types of surface receptors: activating receptors and inhibitory receptors, including killer-cell immunoglobulin-like receptors. Most of these receptors are not unique to NK cells and can be present in some T cell subsets as well.
These inhibitory receptors recognize MHC class I alleles, which could explain why NK cells kill cells possessing low levels of MHC class I molecules. This inhibition is crucial to the role played by NK cells. MHC class I molecules are the main mechanism by which cells display viral or tumor antigens to cytotoxic T cells. A common evolutionary adaptation to this is seen in both intracellular microbes and tumours, the chronic down-regulation of MHC I molecules, rendering the cell impervious to T cell-mediated immunity. It is believed that NK cells evolved as an evolutionary response to this adaptation (the loss of the MHC deprives CD4/CD8 action so another immune cell evolved to fulfill the function). [7]
Tumor cell surveillance[edit]
Natural killer cells often lack antigen-specific cell surface receptors and therefore are part of innate immunity, i.e. able to react immediately with no prior exposure to the pathogen. In both mice and humans, NKs can be seen to play a role in tumor immuno-surveillance by directly inducing the death of tumor cells (NKs act as cytolytic effector lymphocytes), even with the absence of surface adhesion molecules and antigenic peptides. This role of NK cells is critical for immune success particularly because T cells are unable to recognize pathogens in the absence of surface antigens.[1] Tumor cell detection results in activation of NK cells and consequent cytokine production and release.
If the tumor cells do not cause inflammation, they will also be regarded as self and therefore will not induce a T cell response. A number of cytokines are produced by NKs, including tumor necrosis factor α (TNFα), IFNγ, and interleukin (IL-10). TNFα and IL-10 act as pro-inflammatory and immuno-suppressors, respectively. The activation of NK cells and subsequent production of cytolytic effector cells impacts macrophages, dendritic cells, and neutrophils, which subsequently affects antigen-specific T and B cell responses. Instead of acting via antigen-specific receptors, lysis of tumor cells by NK cells is mediated by alternative receptors, including NKG2D, NKp44, NKp46, NKp30, and DNAM.[5] NKG2D is a disulfide-linked homodimer which recognizes a number of ligands, including ULBP and MICA, which are typically expressed on tumor cells.
NK cells, along with macrophages and several other cell types, express the Fc receptor (FcR) molecule (FC-gamma-RIII = CD16), an activating biochemical receptor that binds the Fc portion of antibodies. This allows NK cells to target cells against which a humoral response has been mobilized and to lyse cells through antibody-dependent cellular cytotoxicity (ADCC). This response depends on the affinity of the Fc receptor expressed on NK cells, which can have high, intermediate, and low affinity for the Fc portion of the antibody or IgG. This affinity is determined by the nucleotide status in position 158 of the gene. which can code of phenylalanine (F allele) or valine (V allele). Individuals with high-affinity FcRgammRIII (158 V/V allele) respond better to antibody therapy. This has been shown for lymphoma patients who received the antibody Rituxan. Patients who express the 158 V/V allele had a better anti-tumor response. Only 15-25% of the population expressed the 158 V/V allele. To determine the ADCC contribution of monoclonal antibodies, NK-92 cells (a "pure" NK cell line) has been transfected with the gene for the high-affinity FcR.
NK cell function in adaptive response[edit]
The ability to generate memory cells following a primary infection and the consequent rapid immune activation and response to succeeding infections by the same antigen is fundamental to the role T and B cells play in the adaptive immune response. Despite prior belief that NK cells play no role in the adaptive immune responses, they have since been found to undergo expansion, contraction, memory maintenance and recall.[8]
NK cell function in pregnancy[edit]
As the majority of pregnancies involve two parents who are not tissue matched, successful pregnancy requires the mother's immune system to be suppressed. NK cells are thought to be an important cell type in this process.[9] These cells are known as "uterine NK cells" (uNK cells) and they differ from peripheral NK cells. They are in the CD56bright NK cell subset, potent at cytokine secretion, but with low cytotoxic ability and relatively similar to peripheral CD56bright NK cells, with a slightly different receptor profile.[9] These uNK cells are the most abundant leukocytes present in the uterus in early pregnancy, representing approximately 70% of leukocytes here, however where they originate from remains controversial.[10]
These NK cells have been shown to have the ability to elicit cell cytotoxicity in vitro, however at a lower level than peripheral NK cells, despite containing perforin.[11] Lack of cytotoxicity in vivo may be due to the presence of ligands for their inhibitory receptors. Trophoblast cells downregulate HLA-A and HLA-B in order to defend against cytotoxic T cell-mediated death. This would normally trigger NK cells by missing self recognition, however these cells survive. It is thought that the selective retention of HLA-E (which is a ligand for NK cell inhibitory receptor NKG2A) and HLA-G (which is a ligand for NK cell inhibitory receptor KIR2DL4) by the trophoblast defends it against NK cell-mediated death.[9]
NK cells secrete a high level of cytokines which help mediate their function. Some important cytokines they secrete include TNF-α, IL-10, IFN-γ and TGF-β, among others.[9] For example, IFN-γ dilates and thins the walls of maternal spiral arteries to enhance blood flow to the implantation site.[12]
NK cell evasion by tumor cells[edit]
By shedding decoy NKG2D soluble ligands tumor cells have evolved a process by which they are able to avoid immune responses. These soluble NKG2D ligands bind to NK cell NKG2D receptors activating a false NK response and consequently creating competition for the receptor site.[1] This method of evasion occurs in prostate cancer. In addition, prostate cancer tumors can evade CD8 cell recognition due to the ability to lose expression of MHC class 1 molecules. This example of immune evasion actually highlights NK cell importance in tumor surveillance and response as CD8 cells can consequently only act on tumor cells in response to NK initiated cytokine production (adaptive immune response).[13]
History[edit]
In early experiments on cell-mediated cytotoxicity against tumor target cells, both in cancer patients and animal models, investigators consistently observed what was termed a "natural" reactivity, that is, a certain population of cells seemed to be able to lyse tumor cells without having been previously sensitized to them. As these discoveries were incompatible with the established model at the time, many initially considered that these observations were artifacts.[14] However, by 1973, 'natural killing' activity was established across a wide variety of species, and the existence of a separate lineage of cells possessing this ability was postulated.
The discovery that a unique type of lymphocyte was responsible for “natural” or spontaneous cytotoxicity was made in the early 1970s by doctoral student Rolf Kiessling and post-doctoral fellow Hugh Pross, in the mouse,[15] and by Hugh Pross and doctoral student Mikael Jondal in the human.[16][17] The mouse and human work was carried out under the supervision of professors Eva Klein and Hans Wigzell, respectively, of the Karolinska Institute, Stockholm. Kiessling’s research involved the well-characterized ability of T-lymphocytes to lyse tumor cells against which they had been previously immunized. Pross and Jondal were studying cell-mediated cytotoxicity in normal human blood and the effect of the removal of various receptor-bearing cells on this cytotoxicity. Later that same year Ronald Herberman published similar data with respect to the unique nature of the mouse effector cell.[18] The human data were confirmed, for the most part, by West et al.[19] using similar techniques and the same erythroleukemic target cell line, K562. K562 is highly sensitive to lysis by human NK cells and, over the decades, the K562 51Chromium-release assay has become the most commonly used assay to detect human NK functional activity.[20] Its almost universal use has meant that experimental data can be compared easily by different laboratories around the world.
Using discontinuous density centrifugation and, later, monoclonal antibodies, natural killing ability was mapped to the subset of large, granular lymphocytes known today as NK cells. The demonstration that density gradient-isolated large granular lymphocytes were responsible for human NK activity, made by Timonen and Saksela in 1980,[21] was the first time that NK cells had been visualized microscopically and was a major breakthrough in the field.
New findings[edit]
Anti-cancer therapy[edit]
Since NK cells recognize target cells when they express non-self HLA antigens (but not self), autologous (patients' own) NK cell infusions have not shown any anti-tumor effects. Instead investigators are working on using allogeneic cells from peripheral blood which requires that the T-cells are removed before infusion into the patients as they would otherwise cause graft versus host disease (GvHD) which can be fatal. This can be achieved using an immunomagnetic column (CliniMACS). In addition, because of the limited number of NK cells in blood (only 10% of lymphocytes are NK-cells) their number needs to be expanded in culture. This can take a few weeks and the yield is donor dependent. A simpler way to achieve high numbers of pure NK cells is to expand NK-92 cells NK-92 whose cells continuously grow in culture and can be expanded to clinical grade numbers in bags or bioreactors.[22] Clinical studies have shown that it is well tolerated and some anti-tumor responses have been seen in patients with lung cancer, melanoma and lymphoma.[23][24]
Recent studies at Sloan Kettering Cancer Center and UPenn have shown that infusions of T-cells that were engineered to express a chimeric antigen receptor (CAR) recognizing an antigen molecule on leukemia cells could induce remissions in patients with advanced leukemia. There are logistical challenges of expanding T-cells and investigators are working on applying the same technology to peripheral blood NK cells and NK-92.
In a study at Children's Hospital Boston in coordination with Dana-Farber Cancer Institute, whereby immunocompromised mice had contracted lymphomas from EBV infection, an NK-activating receptor called NKG2D was fused with a stimulatory Fc portion of the EBV antibody. The NKG2D-Fc fusion proved capable of reducing tumor growth and prolonging survival of the recipients. In a transplantation model of LMP1-fueled lymphomas, the NKG2D-Fc fusion proved capable of reducing tumor growth and prolonging survival of the recipients.
Innate resistance to HIV?[edit]
Recent research suggests that specific KIR-MHC class 1 gene interactions could control innate genetic resistance to certain viral infections including HIV and its consequent development of AIDS.[3] Certain HLA allotypes have been found to determine the progression of HIV to AIDS; an example is the HLA-B57 and HLA-B27 alleles, which have been found to defer progression of HIV to AIDS. This is evident because patients expressing these HLA alleles are observed to have lower viral loads and a more gradual decline in CD4+ T cells numbers. Despite considerable research and data collected measuring the genetic correlation of HLA alleles and KIR allotypes, a firm conclusion has not yet been drawn as to what combination provides decreased HIV and AIDS susceptibility. Future research will aim to pinpoint relevant KIR/HLA interactions, to develop a vaccine against HIV/AIDS.
NK cells can impose immune pressure on HIV, something that had previously been described only for T cells and antibodies.[25] HIV mutates to avoid NK cell activity.[25]
See also[edit]
- Innate lymphoid cell
- Active Hexose Correlated Compound
- Granzymes
- Hematopoiesis
- Immune system
- Immunoglobulin, e.g., Ig (above)
- Interleukin, e.g., ILx (above)
- Lymphatic System
Literature[edit]
- Cellular and Molecular Immunology by Abbul K. Abbas & Andrew Lichtman Saunders Copyright 2003
- How the Immune System Works, 2nd edition, by Lauren Sompayrac, PhD Blackwell Publishing 2003
- Immunobiology: The Immune System In Health And Disease by Janeway, Travers, Walport & Shlomchik Churchchill Livingstone Copyright 2005
- Kuby Immunology, 6th edition, by Thomas J. Kindt, Richard A. Goldsby,and Barbara A.OsborneW.H. Freeman and Company,New York
- Tsuda Y, Cygler M, Gibbs BF, et al. (December 1994). "Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors". Biochemistry 33 (48): 14443–51. doi:10.1021/bi00252a010. PMID 7981204.
References[edit]
- ^ a b c Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M. & Ugolini, S. (2011). "Innate or Adaptive Immunity? The Example of Natural Killer Cells". Science 331: 44–49. doi:10.1126/science.1198687.
- ^ Roitt I, Brostoff J, Male D (2001). Immunology (6th ed.), 480p. St. Louis: Mosby, ISBN 0-7234-3189-2.
- ^ a b c Iannello, A., Debbeche, O., Samarani, S., Ahmad, A (2008). "’Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS’". Journal of Leukocyte Biology 84: 1–26. doi:10.1189/jlb.0907650.
- ^ Arina, A., Murillo, O., Dubrot, J., Azpilikueta, A., Alfaro, C., PÃrez-Gracia, J.,L., Bendandi, M., Palencia, B., Hervás-Stubbs, S. & Melero, I. (2007). "'Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer'". Expert Opinion on Biological Therapy 5: 599–615. doi:10.1517/14712598.7.5.599.
- ^ a b Terunuma, H., Deng, X., Dewan, Z., Fujimoto, S., Yamamoto, N. (2008). "Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections". International Reviews of Immunology 27: 93–110. doi:10.1080/08830180801911743.
- ^ Smyth, M.J., Hayakawa, Y., Takeda, K., Yagita. (2002). "New aspects of natural-killer-cell surveillance and therapy of cancer". Nature Review 2: 850–852. doi:10.1038/nrg928.
- ^ Lodoen, M.,B. & Lanier, L.,L. (2005). "Viral modulation of NK cell immunity". Nature Reviews Microbiology 3: 59–69. doi:10.1038/nrmicro1066.
- ^ Pyzik, M. & Vidal, S.,M. (2009). "'NK cells stroll down the memory lane'". Immunology and Cell Biology 87 (4): 261–263. doi:10.1038/icb.2009.10.
- ^ a b c d Lash, G, Robson, S, Bulmer, J. (2010). "Review: Functional role of uterine natural killer (uNK) cells in human early pregnancy decidua". Placenta 31 (S): 87–92. doi:10.1016/j.placenta.2009.12.022. PMID 20061017.
- ^ Bulmer, J, Williams, P, Lash, G (2010). "Immune cells in the placental bed". Int J Dev Biol 54: 281–294. doi:10.1387/ijdb.082763jb. PMID 19876837.
- ^ Kopcow, H et al. (2005). "Human decidual NK cells form immature activating synapses and are not cytotoxic". Proc Natl Acad Sci USA 102: 15563–15568. doi:10.1073/pnas.0507835102. PMC 1266146. PMID 16230631.
- ^ Ashkar AA, Di Santo JP, Croy BA. Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med. 2000 Jul 17;192(2):259-70.
- ^ O'Leary, J.,G., Goodarzi, M., Drayton, D.,L. & von Andrian, U.,H. (2006). "'T cell-and B cell-independent adaptive immunity mediated by natural killer cells'". Nature Immunology 7: 507–516. doi:10.1038/ni1332.
- ^ Oldham R (1983). "Natural killer cells: Artifact to reality: An odyssey in biology". Cancer Metastasis Reviews 2 (4): 323–36. doi:10.1007/BF00048565. PMID 6375859.
- ^ Kiessling R., Klein E., Pross H., Wigzell H. (1975). "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell". Eur. J. Immunol 5 (2): 117–121. doi:10.1002/eji.1830050209. PMID 1086218.
- ^ Pross HF, Jondal M (August 1975). "Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes". Clin. Exp. Immunol. 21 (2): 226–35. PMC 1538269. PMID 810282.
- ^ Jondal M, Pross H (April 1975). "Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations". Int. J. Cancer 15 (4): 596–605. PMID 806545.
- ^ Herberman RB, Nunn ME, Holden HT, Lavrin DH (August 1975). "Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells". Int. J. Cancer 16 (2): 230–9. PMID 1080480.
- ^ Matsukawa H, Okabe E, Sakamoto H, Cho YW, Ito H (April 1978). "Cardiovascular effects of isoproterenol and possible antagonistic actions of propranolol and perhexiline". Jpn. Circ. J. 42 (4): 425–32. PMID 29976.
- ^ Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (January 1981). "Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity". J. Clin. Immunol. 1 (1): 51–63. PMID 7334070.
- ^ Timonen T, Saksela E (1980). "Isolation of human NK cells by density gradient centrifugation". J. Immunol. Methods 36 (3-4): 285–91. PMID 7430655.
- ^ Gong J, Maki G, Klingemann H. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-58
- ^ Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008;10:625-32
- ^ Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001;10:535-44.
- ^ a b http://www.sciencedaily.com/releases/2011/08/110803133509.htm
External links[edit]
- Video of natural killer cell
- CopeWithCytoKines Portal to definitions of NK-Cells and closely related topics
- http://www.hfea.gov.uk/fertility-treatment-options-reproductive-immunology.html Reproductive immunology and fertility treatment
- http://www.cambridgenetwork.co.uk/news/article/default.aspx?objid=58465
- Binns C (June 19, 2006), Natural Body Guards: How Your Killer Cells Get Motivated. Livescience.com. Retrieved on 2007-10-20.
- Natural Killer Cells at the US National Library of Medicine Medical Subject Headings (MeSH)
- Nkcells.info - MediaWiki based information platform specializing on natural killer cells
- Large granular lymphocyte entry in the public domain NCI Dictionary of Cancer Terms
|
Blood: Lymphocytes
|
|
Lymphoid/
HSC:CFU-L |
|
B cells
|
- Plasma
- Memory
- Follicular
- Marginal-zone
- Naive
- Pre-B
|
|
|
Thymocyte
|
|
T cells
|
- αβ (Cytotoxic CD8+
- Helper CD4+ / Th3 / Th17 / Regulatory)
- γδ
- Natural Killer T cell
|
|
|
|
NK cells
|
- Lymphokine-activated killer cell
- Null cell
|
|
|
| Lymphopoiesis |
- Lymphoblast
- Prolymphocyte
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
|
Immunology: Lymphocytic adaptive immune system and complement
|
|
| Lymphoid |
|
Antigens
|
- Antigen presentation/Professional APCs: Dendritic cell
- Macrophage
- B cell
- Immunogen
|
|
|
Antibodies
|
- Antibody
- Monoclonal antibodies
- Polyclonal antibodies
- Autoantibody
- Microantibody
- Polyclonal B cell response
- Allotype
- Isotype
- Idiotype
|
|
|
Immunity vs.
tolerance
|
- action: Immunity
- Autoimmunity
- Alloimmunity
- Allergy
- Hypersensitivity
- Inflammation
- Cross-reactivity
- inaction: Tolerance
- Central
- Peripheral
- Clonal anergy
- Clonal deletion
- Tolerance in pregnancy
- Immunodeficiency
|
|
|
Immunogenetics
|
- Affinity maturation (Somatic hypermutation
- Clonal selection)
- V(D)J recombination
- Junctional diversity
- Immunoglobulin class switching
- MHC/HLA
|
|
|
| Lymphocytes |
- Cellular (T cell)
- Humoral (B cell)
- NK cell
|
|
| Substances |
- Cytokines
- Opsonin
- Cytolysin
|
|
| Complement |
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
